Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
Vicarious Surgical Inc. (symbol: RBOT) is at the forefront of innovation in the field of surgical robotics. The company is dedicated to enhancing the capabilities of surgeons and improving patient outcomes through advanced technological solutions. Vicarious Surgical has developed a unique surgical robot that combines human-like dexterity with the world's first virtual-reality surgical camera, enabling surgeons to perform minimally invasive procedures with the same ease as traditional open surgery.
The company’s flagship product, the Vicarious Surgical Robotic System, is specifically designed for abdominal surgeries. It offers 3D visualization and precise control, all through a single port, which significantly reduces the invasiveness of surgical procedures. This groundbreaking technology aims to expand global access to high-quality surgical care.
Vicarious Surgical's approach redefines what is possible in surgical robotics by integrating cutting-edge virtual reality and robotics technology. The company has achieved significant milestones in recent years, including key partnerships and notable advancements in their robotic systems.
Financially, Vicarious Surgical continues to show promise with robust investments and strategic collaborations that drive its growth and innovation. The company remains committed to pushing the boundaries of medical technology, with ongoing projects focused on further enhancing their systems and expanding their applications.
For investors and stakeholders, Vicarious Surgical represents a compelling opportunity in the rapidly evolving field of medical technology. The company’s mission to improve surgical outcomes and patient care through revolutionary robotics sets it apart as a leader in the industry.
Stay updated with the latest news and developments from Vicarious Surgical to understand its impact and progress in the surgical robotics landscape.
Vicarious Surgical Inc. (RBOT) has announced a Demonstration Day for its Beta 2 surgical robot prototype, scheduled for December 6, 2022, at 11:00 a.m. ET in Waltham, MA. The event is exclusive, with limited in-person attendance by invitation only, but will be live-streamed for broader access. The company aims to enhance surgical efficiency and patient outcomes through innovative robotics technology.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its participation in the Inaugural Gilmartin Group Emerging Growth Company Showcase, scheduled for August 31, 2022, at 11:30 am ET. The virtual event aims to highlight emerging growth companies. Vicarious Surgical focuses on enhancing surgical efficiency and patient outcomes through advanced robotic technology. A live webcast will be available through a provided link, with an archived version accessible on their investor website following the event.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its Q2 2022 financial results, revealing a significant increase in operating expenses to $19.1 million, up from $6.6 million in Q2 2021. Adjusted net loss rose to $19.1 million, or $0.16 per share, compared to a loss of $6.6 million or $0.08 per share in the previous year. The company is advancing its Beta 2 system and partnering with UH Ventures and HCA Healthcare for surgical innovations. Cash burn rate for the quarter was $15.7 million. A conference call will be held today at 4:30 p.m. ET.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) has announced its participation in the Canaccord Genuity 42nd Annual Growth Conference set for Wednesday, August 10 at 9:30 a.m. ET. A live webcast of the presentation will be available on the company’s website, with an archive for later viewing. Founded in 2014 and headquartered in Waltham, Massachusetts, Vicarious Surgical is pioneering robotic technology aimed at enhancing surgical efficiency and patient outcomes while reducing healthcare costs.
Vicarious Surgical Inc. (NYSE: RBOT) will report its second quarter 2022 financial results on August 8, 2022, after market close. A conference call, open to investors, will begin at 4:30 p.m. Eastern Time. The company, founded in 2014, focuses on developing advanced robotics for minimally invasive surgery, aiming to enhance efficiency and reduce healthcare costs. Vicarious Surgical is backed by notable investors, including Bill Gates and Vinod Khosla, and is headquartered in Waltham, Massachusetts.
Vicarious Surgical has entered into Center of Excellence agreements with HCA Healthcare and University Hospitals Ventures. These partnerships aim to enhance the design and commercialization of the Company's robotic surgical system, incorporating real-world feedback from surgeons and healthcare administrators. This collaboration provides Vicarious Surgical with critical insights into surgical workflows, promoting the system's readiness for FDA approval. The partnerships are viewed as significant validation of its in-hospital potential, positioning Vicarious Surgical for future growth in the competitive healthcare market.
Vicarious Surgical Inc. (NYSE: RBOT) will be added to the Russell 3000®, Russell 2000®, and Russell Microcap® Indexes following the annual reconstitution on June 27, 2022. This inclusion recognizes the company as one of the 4,000 largest U.S. stocks based on market capitalization. CEO Adam Sachs expressed that this milestone will enhance institutional visibility and engagement. Russell indexes, which are benchmarks for approximately $12 trillion in assets, offer a significant platform for investors.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its participation in the Cowen 7th Annual FutureHealth Conference. Management will present on June 22 at 10:50 a.m. ET, and a live webcast will be accessible on the company’s website. Founded in 2014 and headquartered in Waltham, Massachusetts, Vicarious Surgical develops advanced robotics technology aimed at improving patient outcomes and reducing healthcare costs through minimally invasive surgeries.
Vicarious Surgical announced its financial results for Q1 2022, reporting a substantial increase in operating expenses to $18.2 million from $5.2 million in Q1 2021, marking a 248% rise. R&D costs rose to $9.8 million, while general and administrative expenses reached $6.9 million. The adjusted net loss was $18.2 million, or $0.15 per share, compared to a loss of $5.2 million, or $0.06 per share, in the previous year. Notably, GAAP net income was $42.5 million, translating to net income per share of $0.35. The company continues to advance its Vicarious System with successful beta testing.
Vicarious Surgical Inc. (NYSE: RBOT) announced it will report financial results for Q1 2022 after market close on May 9, 2022. Management will host a conference call at 4:30 p.m. Eastern Time. Investors can participate by calling +1 (646) 904 5544 for domestic or +1 (929) 526 1599 for international access using code: 646287. The company focuses on enhancing surgical procedures' efficiency and outcomes using proprietary robotic technology. Founded in 2014 and based in Waltham, Massachusetts, Vicarious Surgical is backed by notable investors including Bill Gates.
FAQ
What is the current stock price of Vicarious Surgical (RBOT)?
What is the market cap of Vicarious Surgical (RBOT)?
What does Vicarious Surgical Inc. specialize in?
What is the Vicarious Surgical Robotic System?
How does Vicarious Surgical's technology benefit surgeons?
What makes Vicarious Surgical's approach unique?
Where can I find the latest news about Vicarious Surgical Inc.?
What are the recent achievements of Vicarious Surgical Inc.?
How does the Vicarious Surgical Robotic System improve patient outcomes?
Is Vicarious Surgical Inc. involved in any partnerships?
What is the focus area of Vicarious Surgical's robotic system?
How does Vicarious Surgical's technology expand global access to surgical care?
